Last reviewed · How we verify
NRX194204
At a glance
| Generic name | NRX194204 |
|---|---|
| Sponsor | NuRx Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis (PHASE2)
- Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer (PHASE2)
- Study of IRX4204 for Treatment of Early Parkinson's Disease (PHASE1)
- Oral NRX 194204 in Patients With Refractory Malignancies (PHASE1)
- Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NRX194204 CI brief — competitive landscape report
- NRX194204 updates RSS · CI watch RSS
- NuRx Pharmaceuticals, Inc. portfolio CI